APOA2 and pancreatic neoplasm: The high discrimination capability of ApoAII-2, ApoCIII-0, and their summed value (hereafter denoted as ApoAII-2+CIII-0) between pancreatic cancer patients and controls was validated in an independent cohort consisting of 41 sex- and age-matched healthy controls and 62 pancreatic cancer patients (Cohort 2) (Fig. 4B and Table S3).